Literature DB >> 20394041

Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience.

Kaushang Gandhi1, Wilbert S Aronow, Harit Desai, Harshad Amin, Mala Sharma, Hoang M Lai, Parminder Singh.   

Abstract

BACKGROUND: Cardiovascular manifestation in patients with thrombotic thrombocytopenic purpura. HYPOTHESIS: The aim of this study was to investigate the incidence of acute myocardial infarction (AMI), arrhythmias, congestive heart failure, and mortality in patients hospitalized for thrombotic thrombocytopenic purpura (TTP).
METHODS: Thirty-eight patients (27 women and 11 men), mean age 44 years, were hospitalized with the diagnosis of TTP confirmed by a hematologist. We investigated the incidence of AMI which developed during hospitalization for TTP. AMI was diagnosed by new electrocardiographic changes, increased serum cardiac troponin I levels, and clinical symptomatology. The patients with AMI were also monitored for development of arrhythmias during hospitalization.
RESULTS: Of the 38 patients, 8 (21%) developed new Q-wave AMI. There was no significant difference in baseline characteristics between patients who developed AMI and those who did not develop AMI. Of the 8 patients with AMI, 2 (25%) developed atrial fibrillation, 1 (13%) developed atrial flutter, 1 (13%) developed supraventricular tachycardia, and 2 (25%) developed congestive heart failure. Death occurred in 3 of 8 patients (38%) with AMI and in 1 of 30 patients (3%) without AMI (P < 0.01).
CONCLUSIONS: New Q-wave AMI developed in 21% of 38 patients hospitalized with TTP. Supraventricular tachyarrhythmias developed in 50% of 8 patients with TTP who developed AMI. Patients hospitalized for TTP should be monitored for adverse cardiac events due to the high incidence of new AMI, supraventricular tachyarrhythmias, and mortality. Copyright 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20394041      PMCID: PMC6653000          DOI: 10.1002/clc.20731

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  14 in total

1.  ST-segment elevation myocardial infarction treated with thrombolytic therapy in a patient with thrombotic thrombocytopenic purpura.

Authors:  Jacob A Doll; Jacob P Kelly
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

2.  Causes and risk factors of death in patients with thrombotic microangiopathies.

Authors:  Vincent Peigne; Pierre Perez; Matthieu Resche Rigon; Eric Mariotte; Emmanuel Canet; Jean-Paul Mira; Paul Coppo; Agnès Veyradier; Elie Azoulay
Journal:  Intensive Care Med       Date:  2012-07-14       Impact factor: 17.440

3.  Unresponsive thrombotic thrombocytopenic purpura in critically ill adults.

Authors:  Eric Mariotte; Alice Blet; Lionel Galicier; Michael Darmon; Nathalie Parquet; Etienne Lengline; David Boutboul; Emmanuel Canet; Richard Traineau; Benoît Schlemmer; Agnès Veyradier; Elie Azoulay
Journal:  Intensive Care Med       Date:  2013-04-03       Impact factor: 17.440

4.  Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

5.  Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.

Authors:  Simon F De Meyer; Alexander S Savchenko; Michael S Haas; Daphne Schatzberg; Michael C Carroll; Alexandra Schiviz; Barbara Dietrich; Hanspeter Rottensteiner; Friedrich Scheiflinger; Denisa D Wagner
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

6.  ST segment elevation myocardial infarction as a presenting feature of thrombotic thrombocytopenic purpura.

Authors:  Auras R Atreya; Sonali Arora; Senthil K Sivalingam; Gregory R Giugliano
Journal:  J Cardiovasc Dis Res       Date:  2012-04

7.  Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.

Authors:  Yllka Latifi; Federico Moccetti; Melinda Wu; Aris Xie; William Packwood; Yue Qi; Koya Ozawa; Weihui Shentu; Eran Brown; Toshiaki Shirai; Owen J McCarty; Zaverio Ruggeri; Javid Moslehi; Junmei Chen; Brian J Druker; Jose A López; Jonathan R Lindner
Journal:  Blood       Date:  2019-01-28       Impact factor: 25.476

8.  An autopsy case of myocardial infarction due to idiopathic thrombotic thrombocytopenic purpura.

Authors:  Takashi Tasaki; Sohsuke Yamada; Atsunori Nabeshima; Hirotsugu Noguchi; Aya Nawata; Masanori Hisaoka; Yasuyuki Sasaguri; Toshiyuki Nakayama
Journal:  Diagn Pathol       Date:  2015-05-29       Impact factor: 2.644

Review 9.  Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature.

Authors:  Sami Alasfar; Nada Alachkar
Journal:  Front Med (Lausanne)       Date:  2014-12-12

Review 10.  The standard of care for immune thrombotic thrombocytopenic purpura today.

Authors:  X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-06-30       Impact factor: 16.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.